A Case of Paradoxical Acneiform Eruption Triggered by Ixekizumab.

As a humanized monoclonal antibody targeting interleukin-17A, ixekizumab is increasingly used for the treatment of psoriasis vulgaris. Here, we present a male patient who developed acneiform eruption after using ixekizumab for psoriasis vulgaris. We described acneiform eruption without comedones on the anterior and posterior trunks of a 35-year-old patient with an estimated psoriasis area and severity index score of 32 at the sixth month of treatment. We successfully treated the patient within 1 month with benzoyl peroxide/clindamycin gel and oral azithromycin. Here, acneiform eruption represents a negative event that does not cause discontinuation of ixekizumab. We felt the need to write this case report to raise awareness of the association of this dermatological side effect, which we accept as a paradoxical reaction, with ixekizumab. [ABSTRACT FROM AUTHOR]